| Dr Damon Wood, PHD | |
|
168 Calle De La Ventana, Carmel Valley, CA 93924-9720 | |
| (831) 200-4229 | |
| Not Available |
| Full Name | Dr Damon Wood |
|---|---|
| Gender | Male |
| Speciality | Psychologist - Clinical |
| Location | 168 Calle De La Ventana, Carmel Valley, California |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1831367853 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 103TC0700X | Psychologist - Clinical | PSY24519 (California) | Primary |
| Entity Name | California Telemedicine Associates, P.c. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1073153250 PECOS PAC ID: 7517371859 Enrollment ID: O20210128001414 |
News Archive
Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, announced that top-line final data from its phase 2 clinical trial of PV-10 for metastatic melanoma were presented at the 2nd European Post-Chicago Melanoma Meeting 2012, Interdisciplinary Global Conference on Developing New Treatments for Melanoma, on June 22, 2012, in Munich, Germany.
People who develop Cushing's syndrome as a result of taking systemic glucocorticoids are at very high risk of cardiovascular disease, warn researchers.
"The human immune system makes my head explode," Pulitzer Prize-winning journalist Matt Richtel recently told a University of Alabama at Birmingham freshman seminar on immunology. "This is by far the hardest subject I have ever had to explore."
A new study discusses the development of photosensitized electrospun nanofibrous membranes capable of capturing and inactivating SARS-CoV-2 aerosols.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Damon Wood, PHD Po Box 2212, Carmel Valley, CA 93924-2212 Ph: (831) 200-4229 | Dr Damon Wood, PHD 168 Calle De La Ventana, Carmel Valley, CA 93924-9720 Ph: (831) 200-4229 |
News Archive
Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, announced that top-line final data from its phase 2 clinical trial of PV-10 for metastatic melanoma were presented at the 2nd European Post-Chicago Melanoma Meeting 2012, Interdisciplinary Global Conference on Developing New Treatments for Melanoma, on June 22, 2012, in Munich, Germany.
People who develop Cushing's syndrome as a result of taking systemic glucocorticoids are at very high risk of cardiovascular disease, warn researchers.
"The human immune system makes my head explode," Pulitzer Prize-winning journalist Matt Richtel recently told a University of Alabama at Birmingham freshman seminar on immunology. "This is by far the hardest subject I have ever had to explore."
A new study discusses the development of photosensitized electrospun nanofibrous membranes capable of capturing and inactivating SARS-CoV-2 aerosols.
› Verified 7 days ago